Cadence Pharmaceuticals Inc Revenue Growth Rates (CADX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cadence Pharmaceuticals Inc  (CADX)
 

CADX's Revenue Growth by Quarter and Year

Cadence Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CADX Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December 35.31
3rd Quarter September 28.96
2nd Quarter June 24.67
1st Quarter March 23.61
FY 112.55





CADX Revenue fourth quarter 2013 Y/Y Growth Comment
Cadence Pharmaceuticals Inc reported Revenue surge of 105.67% year on year in the fourth quarter 2013, to $ 35.31 millions, this is lower than Cadence Pharmaceuticals Inc's recent average Revenue surge of 407.84%.

Looking into fourth quarter 2013 results within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue growth. While Cadence Pharmaceuticals Inc' s Revenue doubling of 105.67% ranks overall at the positon no. 277 in the fourth quarter 2013.


CADX Revenue ( Y/Y Growth %) 2013
 2012 2011 2010
4th Quarter December 105.67 % 191.51 % - -
3rd Quarter September 108.35 % 292.66 % - -
2nd Quarter June 122.05 % 60.55 % - -
1st Quarter March 195.13 % 2185.71 % - -
FY   124.3 % 200.48 % - -

Financial Statements
Cadence Pharmaceuticals Inc's fourth quarter 2013 Revenue $ 35.31 millions CADX's Income Statement
Cadence Pharmaceuticals Inc's fourth quarter 2012 Revenue $ 17.17 millions Quarterly CADX's Income Statement


CADX Revenue (Quarter on Quarter Growth %)

 2013
 2012 2011 2010
4th Quarter December 21.94 % 23.53 % 66.38 % -
3rd Quarter September 17.39 % 25.11 % -48.84 % -
2nd Quarter June 4.49 % 38.87 % 1877.14 % -
1st Quarter March 37.51 % 35.82 % - -
FY (Year on Year)   124.3 % 200.48 % - -


Back to CADX Growth rate Comparisons >> Back to CADX Growth rate Comparisons >>


Revenue fourth quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #56
Overall #277

Revenue Y/Y Growth Statistics
High Average Low
2186.86 % 407.84 % 60.61 %
(Dec 31 2013)  
Revenue fourth quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #56
Overall #277
Revenue Y/Y Growth Statistics
High Average Low
2186.86 % 407.84 % 60.61 %
(Dec 31 2013)  

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Cadence Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1876 % 190.74 % -48.8 %
(Jun 30 2011)  


CADX's IV. Quarter Q/Q Revenue Comment
Cadence Pharmaceuticals Inc achieved in the IV. Quarter 2013 below company average Revenue jump of 21.94% quarter on quarter, to $ 35.31 millions.

Within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Cadence Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 726.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #145
Overall #726
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #145
Overall #726
Revenue Q/Q Growth Statistics
High Average Low
1876 % 190.74 % -48.8 %
(Jun 30 2011)  


CADX's IV. Quarter Q/Q Revenue Comment
Cadence Pharmaceuticals Inc achieved in the IV. Quarter 2013 below company average Revenue jump of 21.94% quarter on quarter, to $ 35.31 millions.

Within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Cadence Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 726.


Cadence Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2013)		 12 Months Ending
(Sep 30 2013)		 12 Months Ending
(Jun 30 2013)		 12 Months Ending
(Mar 31 2013)		 12 Months Ending
(Dec 31 2012)
Cumulative Revenue 12 Months Ending $ 112.56 $ 94.42 $ 79.36 $ 65.79 $ 50.18
Y / Y Revenue Growth (TTM) 124.29 % 142.72 % 178.04 % 170.19 % 200.57 %
Year on Year Revenue Growth Overall Ranking # 98 # 0 # 0 # 0 #
Seqeuential Revenue Change (TTM) 19.21 % 18.98 % 20.62 % 31.1 % 29.01 %
Seq. Revenue Growth (TTM) Overall Ranking # 581 # 0 # 0 # 0 #


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2013 period, Cadence Pharmaceuticals Inc's cumulative twelve months Revenue were $ 113 millions, company would post below average annual Revenue growth of 29.01% year on year, if the fiscal year would end at Dec 31 2013.
A slow-down in the Cadence Pharmaceuticals Inc's Revenue growth from the 28.96% growth in Sep 30 2013.

Within the Healthcare sector 26 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 98.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 27
Overall # 98

Revenue TTM Y/Y Growth Statistics
High Average Low
200.57 %
 163.16 %
124.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 89
S&P 500 # 581
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2013 period, Cadence Pharmaceuticals Inc's cumulative twelve months Revenue were $ 113 millions, company would post below average annual Revenue growth of 124.29% year on year, if the fiscal year would end at Dec 31 2013.
A slow-down in the Cadence Pharmaceuticals Inc's Revenue growth from the 28.96% growth in Sep 30 2013.

Within the Healthcare sector 26 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 98.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 27
Overall # 98

Revenue TTM Y/Y Growth Statistics
High Average Low
200.57 %
163.16 %
124.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 89
S&P 500 # 581




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CADX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2013
Tearlab Corp175.65%$ 175.652 millions
Oncomed Pharmaceuticals Inc173.92%$ 173.925 millions
Applied Genetic Technologies Corporation171.05%$ 171.053 millions
Livewire Ergogenics Inc.169.71%$ 169.708 millions
Ontrak Inc 161.45%$ 161.453 millions
Biocryst Pharmaceuticals Inc 157.67%$ 157.669 millions
Elite Pharmaceuticals Inc 153.60%$ 153.601 millions
Axogen inc 150.75%$ 150.750 millions
Bioxytran Inc 149.52%$ 149.523 millions
Cryoport inc 146.56%$ 146.563 millions
Musclepharm Corporation127.34%$ 127.344 millions
Rennova Health Inc 124.00%$ 124.000 millions
Biolife Solutions Inc 117.72%$ 117.719 millions
Molecular Templates Inc 114.60%$ 114.597 millions
Ionis Pharmaceuticals Inc 112.59%$ 112.590 millions
Cadence Pharmaceuticals Inc105.62%$ 105.619 millions
Sanuwave Health Inc 104.10%$ 104.105 millions
Adma Biologics Inc 103.43%$ 103.435 millions
Precision Optics Corporation Inc 102.07%$ 102.069 millions
Protalix Biotherapeutics inc 101.62%$ 101.621 millions
Royalty Pharma Plc100.00%$ 100.000 millions
Addus Homecare Corp99.07%$ 99.071 millions
Novavax inc 91.55%$ 91.548 millions
Beam Therapeutics Inc 88.18%$ 88.182 millions
Allergan plc84.17%$ 84.174 millions
Lannett Company Inc84.13%$ 84.132 millions
Fonar Corporation83.18%$ 83.179 millions
Wearable Health Solutions, Inc.82.45%$ 82.450 millions
Statera Biopharma Inc fka Cytocom Inc 79.12%$ 79.118 millions
Vaxart Inc 78.12%$ 78.124 millions


About Cadence Pharmaceuticals Inc Revenue Growth Rates (CADX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.